论文部分内容阅读
目的:探讨吉他霉素治疗小儿支原体肺炎的疗效及安全性。方法:将160例小儿支原体肺炎患儿随机分为治疗组和对照组各80例,治疗组静脉滴注酒石酸吉他霉素10 mg/(kg.d),7～14 d后改口服吉他霉素,对照组静脉滴注乳糖酸红霉素30 mg/(kg.d),1次/d,7～14 d后改口服红霉素,疗程均为3～4周,比较两组临床疗效和不良反应。结果:治疗组和对照组总有效率分别为96.25%和95.00%,两组总有效率比较差异无统计学意义(P>0.05);吉他霉素治疗组的胃肠道反应、局部静脉疼痛和皮疹等不良反应明显低于红霉素对照组,两组比较差异有统计学意义(P<0.01)。结论:吉他霉素治疗小儿支原体肺炎疗效好,不良反应少,值得临床推广应用。
Objective: To investigate the efficacy and safety of gemcitabine in the treatment of children with mycoplasma pneumonia. Methods: 160 cases of children with mycoplasma pneumonia were randomly divided into treatment group and control group of 80 cases, the treatment group intravenous infusion of Katase tartrate 10 mg / (kg.d), 7 to 14 days after the change of oral giomycin , The control group intravenous infusion of erythromycin lactobionate 30 mg / (kg.d), 1 / d, 7 to 14 d after oral administration of erythromycin, the course of treatment were 3 to 4 weeks, the clinical efficacy and Adverse reactions. Results: The total effective rates of the treatment group and the control group were 96.25% and 95.00%, respectively. There was no significant difference in the total effective rate between the two groups (P> 0.05). The gastrointestinal reactions, local venous pain, Rash and other adverse reactions were significantly lower than the erythromycin control group, the difference between the two groups was statistically significant (P <0.01). Conclusion: The effect of the treatment of Mycoplasma pneumonia with Katamycin is good and the adverse reactions are few. It is worthy of clinical application.